|
1
|
Fendler A, Jung M, Stephan C, Honey RJ,
Stewart RJ, Pace KT, Erbersdobler A, Samaan S, Jung K and Yousef
GM: miRNAs can predict prostate cancer biochemical relapse and are
involved in tumor progression. Int J Oncol. 39:1183–1192.
2011.PubMed/NCBI
|
|
2
|
van Brussel JP and Mickisch GH: Multidrug
resistance in prostate cancer. Onkologie. 26:175–181.
2003.PubMed/NCBI
|
|
3
|
Tannock IF, de Wit R, Berry WR, Horti J,
Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et
al; TAX 327 Investigators. Docetaxel plus prednisone or
mitoxantrone plus prednisone for advanced prostate cancer. N Engl J
Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Simpson RJ, Lim JW, Moritz RL and
Mathivanan S: Exosomes: Proteomic insights and diagnostic
potential. Expert Rev Proteomics. 6:267–283. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Camussi G, Deregibus MC, Bruno S,
Cantaluppi V and Biancone L: Exosomes/microvesicles as a mechanism
of cell-to-cell communication. Kidney Int. 78:838–848. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
An T, Qin S, Xu Y, Tang Y, Huang Y, Situ
B, Inal JM and Zheng L: Exosomes serve as tumour markers for
personalized diagnostics owing to their important role in cancer
metastasis. J Extracell Vesicles. 4:275222015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang J, Li S, Li L, Li M, Guo C, Yao J
and Mi S: Exosome and exosomal microRNA: Trafficking, sorting, and
function. Genomics Proteomics Bioinformatics. 13:17–24. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hannafon BN, Carpenter KJ, Berry WL,
Janknecht R, Dooley WC and Ding WQ: Exosome-mediated microRNA
signaling from breast cancer cells is altered by the
anti-angiogenesis agent docosahexaenoic acid (DHA). Mol Cancer.
14:1332015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang M, Chen J, Su F, Yu B, Su F, Lin L,
Liu Y, Huang JD and Song E: Microvesicles secreted by macrophages
shuttle invasion-potentiating microRNAs into breast cancer cells.
Mol Cancer. 10:1172011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li F, Danquah M, Singh S, Wu H and Mahato
RI: Paclitaxel- and lapatinib-loaded lipopolymer micelles overcome
multidrug resistance in prostate cancer. Drug Deliv Transl Res.
1:420–428. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lässer C, Eldh M and Lötvall J: Isolation
and characterization of RNA-containing exosomes. J Vis Exp.
9:e30372012.
|
|
12
|
Vlachos IS, Kostoulas N, Vergoulis T,
Georgakilas G, Reczko M, Maragkakis M, Paraskevopoulou MD,
Prionidis K, Dalamagas T and Hatzigeorgiou AG: DIANA miRPath v.2.0:
Investigating the combinatorial effect of microRNAs in pathways.
Nucleic Acids Res. 40(W1): W498–504. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bian Z, Li LM, Tang R, Hou DX, Chen X,
Zhang CY and Zen K: Identification of mouse liver
mitochondria-associated miRNAs and their potential biological
functions. Cell Res. 20:1076–1078. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang C, Wang C, Chen X, Yang C, Li K,
Wang J, Dai J, Hu Z, Zhou X, Chen L, et al: Expression profile of
microRNAs in serum: A fingerprint for esophageal squamous cell
carcinoma. Clin Chem. 56:1871–1879. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Iorio MV and Croce CM: microRNA
involvement in human cancer. Carcinogenesis. 33:1126–1133. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Makino DL, Halbach F and Conti E: The RNA
exosome and proteasome: Common principles of degradation control.
Nat Rev Mol Cell Biol. 14:654–660. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Janowska-Wieczorek A, Wysoczynski M,
Kijowski J, Marquez-Curtis L, Machalinski B, Ratajczak J and
Ratajczak MZ: Microvesicles derived from activated platelets induce
metastasis and angiogenesis in lung cancer. Int J Cancer.
113:752–760. 2005. View Article : Google Scholar
|
|
19
|
Kruger S, Abd Elmageed ZY, Hawke DH,
Wörner PM, Jansen DA, Abdel-Mageed AB, Alt EU and Izadpanah R:
Molecular characterization of exosome-like vesicles from breast
cancer cells. BMC Cancer. 14:442014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou Y, Wan G, Spizzo R, Ivan C, Mathur R,
Hu X, Ye X, Lu J, Fan F, Xia L, et al: miR-203 induces oxaliplatin
resistance in colorectal cancer cells by negatively regulating ATM
kinase. Mol Oncol. 8:83–92. 2014. View Article : Google Scholar :
|
|
21
|
Ru P, Steele R, Hsueh EC and Ray RB:
Anti-miR-203 upregulates SOCS3 expression in breast cancer cells
and enhances cisplatin chemosensitivity. Genes Cancer. 2:720–727.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang R, Chen DQ, Huang JY, Zhang K, Feng
B, Pan BZ, Chen J, De W and Chen LB: Acquisition of radioresistance
in docetaxel-resistant human lung adenocarcinoma cells is linked
with dysregulation of miR-451/c-Myc-survivin/rad-51 signaling.
Oncotarget. 5:6113–6129. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu H, Wu H, Liu X, Evans BR, Medina DJ,
Liu CG and Yang JM: Role of MicroRNA miR-27a and miR-451 in the
regulation of MDR1/P-glycoprotein expression in human cancer cells.
Biochem Pharmacol. 76:582–588. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jin AH, Zhou XP and Zhou FZ: Inhibition of
microRNA-23a increases cisplatin sensitivity of ovarian cancer
cells: The possible molecular mechanisms. Nan Fang Yi Ke Da Xue Xue
Bao. 35:125–128. 2015.(In Chinese). PubMed/NCBI
|
|
25
|
Tanaka S, Hosokawa M, Yonezawa T, Hayashi
W, Ueda K and Iwakawa S: Induction of epithelial-mesenchymal
transition and down-regulation of miR-200c and miR-141 in
oxaliplatin-resistant colorectal cancer cells. Biol Pharm Bull.
38:435–440. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu L, Zou J, Wang Q, Yin FQ, Zhang W and
Li L: Novel microRNAs expression of patients with chemotherapy
drug-resistant and chemotherapy-sensitive epithelial ovarian
cancer. Tumour Biol. 35:7713–7717. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang L, Mezencev R, Švajdler M, Benigno BB
and McDonald JF: Ectopic over-expression of miR-429 induces
mesenchymal-to-epithelial transition (MET) and increased drug
sensitivity in metastasizing ovarian cancer cells. Gynecol Oncol.
134:96–103. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu D, Xia P, Diao D, Cheng Y, Zhang H,
Yuan D, Huang C and Dang C: MiRNA-429 suppresses the growth of
gastric cancer cells in vitro. J Biomed Res. 26:389–393. 2012.
View Article : Google Scholar
|
|
29
|
Xu Y, Ohms SJ, Li Z, Wang Q, Gong G, Hu Y,
Mao Z, Shannon MF and Fan JY: Changes in the expression of miR-381
and miR-495 are inversely associated with the expression of the
MDR1 gene and development of multi-drug resistance. PLoS One.
8:e820622013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Benassi B, Marani M, Loda M and Blandino
G: USP2a alters chemotherapeutic response by modulating redox. Cell
Death Dis. 4:e8122013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hoque MO, Brait M, Rosenbaum E, Poeta ML,
Pal P, Begum S, Dasgupta S, Carvalho AL, Ahrendt SA, Westra WH, et
al: Genetic and epigenetic analysis of erbB signaling pathway genes
in lung cancer. J Thorac Oncol. 5:1887–1893. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu G, Qin XQ, Guo JJ, Li TY and Chen JH:
AKT/ERK activation is associated with gastric cancer cell
resistance to paclitaxel. Int J Clin Exp Pathol. 7:1449–1458.
2014.PubMed/NCBI
|
|
33
|
Jathal MK, Chen L, Mudryj M and Ghosh PM:
Targeting ErbB3: the new RTK(id) on the prostate cancer block.
Immunol Endocr Metab Agents Med Chem. 11:131–149. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Figel S and Gelman IH: Focal adhesion
kinase controls prostate cancer progression via intrinsic kinase
and scaffolding functions. Anticancer Agents Med Chem. 11:607–616.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee BY, Hochgräfe F, Lin HM, Castillo L,
Wu J, Raftery MJ, Martin Shreeve S, Horvath LG and Daly RJ:
Phosphoproteomic profiling identifies focal adhesion kinase as a
mediator of docetaxel resistance in castrate-resistant prostate
cancer. Mol Cancer Ther. 13:190–201. 2014. View Article : Google Scholar
|
|
36
|
Kang Y, Hu W, Ivan C, Dalton HJ, Miyake T,
Pecot CV, Zand B, Liu T, Huang J, Jennings NB, et al: Role of focal
adhesion kinase in regulating YB-1-mediated paclitaxel resistance
in ovarian cancer. J Natl Cancer Inst. 105:1485–1495. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Seo YH, Jo YN, Oh YJ and Park S:
Nano-mechanical reinforcement in drug-resistant ovarian cancer
cells. Biol Pharm Bull. 38:389–395. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Darshan MS, Loftus MS, Thadani-Mulero M,
Levy BP, Escuin D, Zhou XK, Gjyrezi A, Chanel-Vos C, Shen R, Tagawa
ST, et al: Taxane-induced blockade to nuclear accumulation of the
androgen receptor predicts clinical responses in metastatic
prostate cancer. Cancer Res. 71:6019–6029. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gan L, Chen S, Wang Y, Watahiki A, Bohrer
L, Sun Z, Wang Y and Huang H: Inhibition of the androgen receptor
as a novel mechanism of taxol chemotherapy in prostate cancer.
Cancer Res. 69:8386–8394. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Alimirah F, Chen J, Basrawala Z, Xin H and
Choubey D: DU-145 and PC-3 human prostate cancer cell lines express
androgen receptor: Implications for the androgen receptor functions
and regulation. FEBS Lett. 580:2294–2300. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mizoguchi M, Nutt CL, Mohapatra G and
Louis DN: Genetic alterations of phosphoinositide 3-kinase subunit
genes in human glioblastomas. Brain Pathol. 14:372–377. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kohno T, Takahashi M, Manda R and Yokota
J: Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers.
Genes Chromosomes Cancer. 22:152–156. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jiang J and Huang H: Targeting the
Androgen Receptor by taxol in castration-resistant prostate cancer.
Mol Cell Pharmacol. 2:1–5. 2010.PubMed/NCBI
|
|
44
|
van de Wetering M, Sancho E, Verweij C, de
Lau W, Oving I, Hurlstone A, van der Horn K, Batlle E, Coudreuse D,
Haramis AP, et al: The beta-catenin/TCF-4 complex imposes a crypt
progenitor phenotype on colorectal cancer cells. Cell. 111:241–250.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shin HW, Choi H, So D, Kim YI, Cho K4,
Chung HJ5, Lee KH6, Chun YS7, Cho CH1, Kang GH, et al: ITF2
prevents activation of the beta-catenin-TCF4 complex in colon
cancer cells and levels decrease with tumor progression.
Gastroenterology. 147:430–442.e438. 2014. View Article : Google Scholar
|
|
46
|
Gheidari F, Bakhshandeh B,
Teimoori-Toolabi L, Mehrtash A, Ghadir M and Zeinali S: TCF4
silencing sensitizes the colon cancer cell line to oxaliplatin as a
common chemotherapeutic drug. Anticancer Drugs. 25:908–916. 2014.
View Article : Google Scholar : PubMed/NCBI
|
